Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Cancer Epigenetics: Clinical Perspectives

Author(s): Aamir Ahmad

Volume 19, Issue 7, 2019

Page: [513 - 514] Pages: 2

DOI: 10.2174/156800961907190802112321

Next »
[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2019, 69, 7-34.
[2]
Ahmad, A. Editorial: Cancer epigenetics. Curr. Cancer Drug Targets, 2018, 18, 3-4.
[3]
Fang, F.; Cardenas, H.; Huang, H.; Jiang, G.; Perkins, S.M.; Zhang, C.; Keer, H.N.; Liu, Y.; Nephew, K.P.; Mate, D. Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer Res., 2018, 78, 631-644.
[4]
Stieglitz, E.; Mazor, T.; Olshen, A.B.; Geng, H.; Gelston, L.C.; Akutagawa, J.; Lipka, D.B.; Plass, C.; Flotho, C.; Chehab, F.F.; Braun, B.S. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat. Commun., 2017, 8, 2127.
[5]
Pineda, B.; Diaz-Lagares, A.; Perez-Fidalgo, J.A.; Burgues, O.; Gonzalez-Barrallo, I.; Crujeiras, A.B.; Sandoval, J.; Esteller, M.; Lluch, A.; Eroles, P. A two-gene epigenetic signature for the prediction of response to neo adjuvant chemotherapy in triple-negative breast cancer patients. Clin. Epigenetics, 2019, 11, 33.
[6]
Connolly, R.M.; Fackler, M.J.; Zhang, Z.; Zhou, X.C.; Goetz, M.P.; Boughey, J.C.; Walsh, B.; Carpenter, J.T.; Storniolo, A.M.; Watkins, S.P.; Gabrielson, E.W. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res. Treat., 2018, 167, 107-116.
[7]
Barault, L.; Amatu, A.; Siravegna, G.; Ponzetti, A.; Moran, S.; Cassingena, A.; Mussolin, B.; Falcomatà, C.; Binder, A.M.; Cristiano, C.; Oddo, D. Discover y of methylated circulating DNA biomarkrs for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.
[8]
Belinsky, S.A.; Leng, S.; Wu, G.; Thomas, C.L.; Picchi, M.A.; Lee, S.J.; Aisner, S.; Ramalingam, S.; Khuri, F.R.; Karp, D.D. Gene methylation biomarkers in sputum and plasma as predictors for lung cancer recurrence. Cancer Prev. Res. (Phila.), 2017, 10, 635-640.
[9]
Guo, R.Q.; Xiong, G.Y.; Yang, K.W.; Zhang, L.; He, S.M.; Gong, Y.Q.; He, Q.; Li, X.Y.; Wang, Z.C.; Bao, Z.Q.; Li, X.S. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. Urol. Oncol., 2018, 36, e315-e342.
[10]
Kirkin, A.F.; Dzhandzhugazyan, K.N.; Guldberg, P.; Fang, J.J.; Andersen, R.S.; Dahl, C.; Mortensen, J.; Lundby, T.; Wagner, A.; Law, I.; Broholm, H. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nat. Commun., 2018, 9, 785.
[11]
Stein, E.M.; Garcia-Manero, G.; Rizzieri, D.A.; Tibes, R.; Berdeja, J.G.; Savona, M.R.; Jongen-Lavrenic, M.; Altman, J.K.; Thomson, B.; Blakemore, S.J.; Daigle, S.R. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669.
[12]
Ahmad, A. Epigenetics in personalized management of lung cancer. Adv. Exp. Med. Biol., 2016, 890, 111-122.
[13]
O’Reilly, E.; Tuzova, A.V.; Walsh, A.L.; Russell, N.M.; O’Brien, O.; Kelly, S.; Dhomhnallain, O.N.; DeBarra, L.; Dale, C.M.; Brugman, R.; Clarke, G. epiCaPture: A urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol, 2019, 3, 1-18.

Rights & Permissions Print Cite
Article Metrics
20
5
1
1
© 2024 Bentham Science Publishers | Privacy Policy